Mary Beth Harler Net Worth

The estimated Net Worth of Mary Beth Harler is at least $1.01 Million dollars as of 14 June 2024. Mary Harler owns over 1,570 units of IGM Biosciences stock worth over $1,000,565 and over the last few years Mary sold IGMS stock worth over $11,901.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mary Harler IGMS stock SEC Form 4 insiders trading

Mary has made over 1 trades of the IGM Biosciences stock since 2024, according to the Form 4 filled with the SEC. Most recently Mary sold 1,570 units of IGMS stock worth $11,901 on 14 June 2024.

The largest trade Mary's ever made was selling 1,570 units of IGM Biosciences stock on 14 June 2024 worth over $11,901. On average, Mary trades about 785 units every 0 days since 2024. As of 14 June 2024 Mary still owns at least 85,227 units of IGM Biosciences stock.

You can see the complete history of Mary Harler stock trades at the bottom of the page.

What's Mary Harler's mailing address?

Mary's mailing address filed with the SEC is C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW, CA, 94043.

Insiders trading at IGM Biosciences

Over the last 5 years, insiders at IGM Biosciences have traded over $2,263,330 worth of IGM Biosciences stock and bought 10,358,723 units worth $195,788,133 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Group, Llc Green Jeremy Red..., and Bros. Advisors Lp667, L.P.B.... On average, IGM Biosciences executives and independent directors trade stock every 13 days with the average trade being worth of $942,182. The most recent stock trade was executed by Julie Hambleton on 25 July 2024, trading 15,132 units of IGMS stock currently worth $21,033.

What does IGM Biosciences do?

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Complete history of Mary Harler stock trades at IGM Biosciences

IGM Biosciences executives and stock owners

IGM Biosciences executives and other stock owners filed with the SEC include:

• Fred M. Schwarzer J.D.,
  CEO, Pres & Director
• Fred Schwarzer,
  President, Chief Executive Officer, Director
• Dr. Shinyu Chen M.D., Ph.D.,
  Consultant
• Dr. Chris H. Takimoto FACP, M.D., Ph.D.,
  Chief Medical Officer
• Dr. Bruce A. Keyt,
  Chief Scientific Officer
• Fred M. Schwarzer,
  CEO, Pres & Director
• Bruce Keyt,
  Chief Scientific Officer
• Misbah Tahir,
  Chief Financial Officer
• Michael Loberg,
  Independent Chairman of the Board
• M. Kathleen Behrens,
  Independent Director
• Julie Hambleton,
  Independent Director
• William Strohl,
  Independent Director
• Christina Topsoe,
  Independent Director
• Kelvin Neu,
  Independent Director
• Jakob Topsoe,
  Independent Director
• Michael Lee,
  Independent Director
• David Pitts,
  IR Contact Officer
• Daniel Chen,
  Chief Medical Officer
• Steven Weber,
  SVP, Corp. Controller & Principal Accounting Officer
• Marvin S. Peterson Ph.D.,
  Sr. VP, Process Sciences & Manufacturing
• George A. Gauthier,
  Chief Commercial Officer
• Dr. Lisa L. Decker Ph.D.,
  Chief Bus. Officer
• Misbah Tahir,
  Chief Financial Officer
• Angus Sinclair,
  VP of Immuno-Oncology
• Suzette Tauber,
  VP of HR
• Paul C. Graffagnino,
  VP of Legal Affairs
• Mary Beth Harler,
  Head, Research & Autoimmunity
• Group, Llc Green Jeremy Red...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Holding A/S Topsoe,
  10% owner
• Chris H Takimoto,
  CHIEF MEDICAL OFFICER
• Bros. Advisors Lp667, L.P.B...,
  
• Lisa Lynn Decker,
  CHIEF BUSINESS OFFICER
• George Gauthier,
  Chief Commercial Officer
• Steven Weber,
  PRINCIPAL ACCOUNTING OFFICER
• Elizabeth H.Z. Thompson,
  
• Bros. Advisors Lp667, L.P.B...,